Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04861584
Other study ID # GZZJU-2021NB
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date June 3, 2021
Est. completion date April 3, 2025

Study information

Verified date January 2023
Source Zhujiang Hospital
Contact Abai Xu, doctor
Phone +86 18665626790
Email lc96xab@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a pre-surgical study involving subjects with local advanced bladder cancer, who are candidates for neoadjuvant therapy. It is a single-arm phase II portion.


Description:

Outline: This study is a single-arm, open, exploratory clinical trial; Subjects receive: gemcitabine 1000mg/m2 IV Day1 and Day8 every 21 days repeated for 4 cycles; cisplatin 35mg/m2 IV Day1 and Day2 every 21 days, repeated for 4 cycles. Toripalimab at recommended phase II dose is given every 3 weeks for 4 doses starting with Cycle1 Day1(C1D1). Subjects will then have surgery to remove their primary tumor within 6 weeks after their last dose of neoadjuvant therapy. Eastern Cooperative Oncology Group (ECOG) performance status: 0-1 Demonstrate adequate organ function as defined by the following laboratory values at study entry. All screening labs should be performed within 28 days of C1D1. Hematopoetic: Absolute neutrophil count (ANC) ≥1,500 /mcL Absolute lymphocyte count ≥350 mcL Platelets ≥100,000 / mcL Hemoglobin ≥9 g/dL or ≥5.6 mmol/L Renal: Measured or calculated creatinine clearance ≥30 mL/min Hepatic: Serum total bilirubin ≤ 1.25 X ULN OR ≤ 2.5 x ULN for subjects with Gilbert's disease Aspartate aminotransferase (AST, SGOT) and alanine aminotransferase (ALT, SGPT) ≤ 2 X ULN Coagulation: International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants Activated Partial Thromboplastin Time (aPTT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy and as long as PT or PTT is within therapeutic range of intended use of anticoagulants


Recruitment information / eligibility

Status Recruiting
Enrollment 41
Est. completion date April 3, 2025
Est. primary completion date October 3, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Patients between 18 and 75 years old on day of signing informed consent, regardless of gender; - ECOG score 0-1 points, expected survival time> 6 months; - Pathologically confirmed locally advanced bladder urothelial carcinoma (cT2-T4a, N=1, M0, tumor staging according to American Joint Committee on Cancer (AJCC), 2017, eighth edition); - Appropriate and plan for radical cystectomy; - According to the RECIST1.1 standard, there is at least one measurable lesion (spiral CT scan =10mm); - Since the diagnosis of locally advanced bladder urothelial carcinoma, patient has not received anti-tumor system treatment; - The main organ functions are normal, and the following requirements must be met within 2 weeks before the first study treatment: - Routine blood examination must meet: WBC=4.0×109/L; PLT=90×109/L; Hb=90g/L (patients can be infused with red blood cells to meet this standard); - Blood biochemical examination must meet: serum creatinine (Cr) =1.5 times the upper limit of normal (ULN) or endogenous creatinine clearance =60mL/min; TBIL=1.5×ULN; ALB=30g/L; ALT and AST= 3.0×ULN; TSH=1.5×ULN. - Female patients with fertility must undergo a pregnancy test (serum or urine) within 7 days before enrollment, and the result is negative, and they voluntarily adopt appropriate methods of contraception during the observation period and within 8 weeks after the last administration; - Agree to provide diagnosis and treatment-related tumor tissue specimens for clinical research, and have the ability to follow the planned research visit until the clinical recurrence/progress is clear. - Sign informed consent voluntarily. Exclusion Criteria: - Have previously received anti-PD1/PDL1/CTLA-4 antibody treatment or systemic chemotherapy, bladder infusion chemotherapy is excluded; - Have received bladder bacille Calmette Guerin (BCG) infusion therapy within 4 weeks; - Have received radiotherapy of the bladder in the past; - Patients with any history of active autoimmune disease or autoimmune disease; - Complicated diseases that require the use of immunosuppressive drugs; concurrent diseases that require the use of immunosuppressive agents for systemic or locally absorbable corticosteroids. It is forbidden to use prednisone greater than 10 mg/day or the same dose in the 2 weeks before the use of the study drug; - Combined with other malignant tumors; - Have a history of allergy to other antibody drugs; - The history of human immunodeficiency virus (HIV) infection; - The subject has active infection, including active tuberculosis; - Combined with severe heart disease, or combined with New York Heart Association (NYHA) grade 3 or 4 cardiac insufficiency; - Kidney transplant patients;

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin
4 cycle neoadjuvant therapy and radical cystectomy

Locations

Country Name City State
China Zhujiang Hospital Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Zhujiang Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pathological response rate evaluated after 4 cycles of neoadjuvant Toripalimab in combination with gemcitabine and cisplatin at time of radical cystectomy, each cycle is 21 days the absence of residual muscle invasive bladder cancer in surgical specimens of cystectomy (pathologically decreased to =pT1N0, including pT0, pT1, pTa and pTis Up to 90 days after last dose of investigation product
Secondary Safety assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v.) 4 criteria To assess safety of Toripalimab in combination with gemcitabine and cisplatin in patients with bladder cancer according to CTCAE v4 criteria From the first day of the treatment to the end of neoadjuvant treatment, assessed up to 6 month
Secondary Progression-free survival assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 From the start of neoadjuvant therapy to the time when any disease progression is first recorded, disease progression includes the progression detected by clinical or imaging before cystectomy, as well as the distant metastasis or pelvic recurrence after cystectomy. Newly discovered primary tumors in other parts of the urinary tract such as renal pelvis, ureter and urethra are not considered as disease progression. From the start of neoadjuvant therapy to the time when any disease progression is first recorded. Assessed lasted for 24 months, calculated from the date of enrolled
Secondary Tumor immune microenvironment indicators assessed by Microenvironment Analysis Panel The expression rate of PDL1 in pathological specimens assessed by Burning Rock's product OncoScreen plus+Microenvironment Analysis Panel at the time of surgery Assessed lasted for 24 months, calculated from the date of enrolled
See also
  Status Clinical Trial Phase
Recruiting NCT00872495 - Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer
Withdrawn NCT05335707 - Longitudinal Geriatric Assessment to Optimize Outcomes of Older Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy
Completed NCT03998579 - Physical Rehabilitation Among Patients Undergoing Radical Cystectomy Due to Urinary Bladder Cancer N/A
Not yet recruiting NCT04525781 - Clinicoepidimiological Study and Clinical Outcome in Patients With Urinary Bladder Cancer
Completed NCT02897765 - A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer Phase 1
Recruiting NCT05822934 - Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer Phase 3
Completed NCT06156787 - Patterns of Urinary Bladder Cancer in Darfur, Suda
Completed NCT02722538 - Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer Phase 1
Completed NCT02437539 - Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography Phase 1
Completed NCT02139371 - Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography Phase 0
Completed NCT03433924 - An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients.
Active, not recruiting NCT03132922 - MAGE-A4ᶜ¹º³²T for Multi-Tumor Phase 1
Completed NCT05946369 - Neutrophils to Lymphocytes Ratio in Predicting the Response to BCG in Non-muscle Invasive Bladder Cancer
Completed NCT00462488 - Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ Phase 2
Recruiting NCT05621837 - Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
Recruiting NCT05644041 - Intravesical Gemcitabine in Patients With NMIBC Phase 2
Completed NCT04635566 - Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute N/A
Completed NCT01836978 - Prehabilitation to Enhance Postoperative Functional Capacity Following Radical Cystectomy N/A
Terminated NCT01374789 - PURO Panitumumab in Combination With Gemcitabine/Cisplatin in Advanced Urothelial Cancer Phase 2
Recruiting NCT03844256 - A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study Phase 1/Phase 2